Soybean glycinin |
IAVPGEVA IAVPTGVA LPYP |
HepG2 cells |
Anti-hypocholesterolemic |
Inhibit 3-hydroxymethylglutaryl coenzyme A (HMGCoA) reductase and stimulate the LDL receptor pathway which in turn reduces the cholesterol |
(19) |
Mature and young soybean proteins hydrolysates |
FPFPRPPHQ, FMYL, MMLM, SFFFPFELPRE |
Pancreatic lipase (PL) and cholesterol esterase (C-Ease) enzymes |
Anti-lipidemic |
Compared to flavorzyme and alcalase, bromelain showed higher levels of protein degradation, and its hydrolysis resulted in enhanced PL and C-Ease inhibition effectiveness. FPFPRPPHQ, FMYL, MMLM, and SFFFPFELPRE were effective inhibitors of the C-Ease enzyme. FPFPRPPHQ and SFFFPFELPRE had inhibitory potencies against both PL and C-Ease |
(42) |
Soybean |
VHVV |
Rats |
Anti-hypertensive |
Reduced p-PI3K, p-AKT, anti-apoptosis proteins (Bcl2 and Bcl-XL), SIRT1, and FOXO3 in rats. Activated cell survival, AMPKα1, Sirt1, PGC1α, and FoX3α proteins |
(43, 44) |
Soy protein hydrolysates |
ILL LLL VHVV |
HepG2 cells |
Anti-obesity |
Hydrolysates of soybean may reduce serum levels of triglycerides by decreasing fatty acid synthase (13.6) than control (17.0) |
(6) |
Soybean meal fermented by Bacillus subtilis E20 |
KHPHGRSYKTKLRILA LRFRAPAPVLRRIAKR HTSKALLDMLKRLGK |
Shrimp |
Anti-bacterial |
Effective against microbes Vibrio alginolyticus and V. parahaemolyticus
|
(45, 46) |
Soybean |
PGTAVFK |
In vitro
|
Anti-bacterial |
At a concentration of 31 M, PGTAVFK also exhibits antibacterial action against E. coli and S. aureus
|
(47, 48) |
Cheese peptidome |
KFVPKQPNMIL |
Glycoprotein receptor-binding domain (RBD) and main protease (3CLPro) |
Anti-viral activity |
Cheese peptidome could be used against the SARS-CoV-2 virus with binding energy values ranging from −8.45 to −26.8 kcal/mol and −15.22 to −22.85 kcal/mol to inhibit viruses' effect |
(49) |
Soy cheese fermented by Lactobacillus delbrueckii WS4 |
KFVPKQPNMIL |
Human red blood cells |
Anti-viral |
Soy cheese is made with Lb. delbrueckii WS4 could be potential meal for SARS-CoV-2 and related viruses' prophylaxis |
(49, 50) |
Glycinin |
IAVPTGVA LPYP |
Caco-2 cells in the intestine of humans and HK-2 cells in the kidney |
ACE enzyme inhibition |
The activity of the ACE enzyme of renal and intestinal get decreased enzyme activity with desired IC50 values of 14.7 ± 0.28 and 5.0 ± 0.28 μM for Caco-2 cells, and 6.0 ± 0.35 and 6.8 ± 0.20 μM for HK-2 cells |
(51, 52) |
Soybean |
PGTAVFK IKAFKEATKVVVVLWTA |
In vitro
|
Anti-bacterial |
Inhibitory concentration of 37.2 M, the peptide with long chain (IKAFKEATKVVVVLWTA) is more efficient in opposing Listeria monocytogenes and Pseudomonas aeruginosa
|
(53, 54) |
Soybean protein concentrate |
FPLLVLLGTVFLASVCVSLKVREDE NNPFYFR FFEITPEKN- PQLRDLDIFLSSVDINEGALLLPHFNSK |
In vitro
|
Antioxidant and inhibitory assay |
High molecular mass peptides demonstrated maximum antioxidant activity than low molecular mass peptides, however in case of inhibitory activities, low molecular peptides resulted better effects for α -glucosidase inhibition (IC50 = 0.94) and lipases (IC50 = 4.06) than high molecular peptides inhibition of α-glucosidase (IC50 = 3.4) and of pancreatic lipase (IC50 = 2.02) |
(55) |
Germinated soybean protein digest |
VVNPDNNEN QEPQESQQ SDESTESETEQA |
Human colon cancer cells, mouse macrophages RAW 264.7 |
Anticancer and anti-inflammatory effects |
Fractions, 5–10 kDa peptides revealed maximum showed potency with IC50 = 11.70 mg/mL as compared to >10 kDa, which showed IC50 = 13.21 mg/mL values against cancer while 45% inhibition observed against inflammation |
(56–58) |
Soybean |
SKWQHQQDSC RKQKQGVNLT PCEKHIMEKI QGRGDDDDDDD DD |
Mice |
Hypocholesterolemic |
After 4 weeks of receiving lunasin with 0.125–0.5 μmol/kg·day dose mice had remarkably low PCSK9 and high amounts of LDLR levels in hepatic tissue, moreover, it decreased total-cholesterol (T-CHO), LDL-C in blood and up-regulated LDLR in HepG2 cells |
(59) |
β-conglycinin |
YVVNPDNDEN |
Mouse liver |
Anti-obesity |
Weight of adipose tissue reduced by increasing postprandial circulating FGF21 |
(60) |
Soybean protein |
EKPQQQSSRRGS |
Mice |
Immunomodulatory effect |
Enhanced phagocytosis, retard excessive inflammatory response, and induced macrophages M1 polarization in the spleen of mice |
(61) |
Soy protein isolate (bromelain and thermolysin) |
- |
Human oral squamous carcinoma cell line, HSC-3 |
Anti-proliferative activity |
After 72 h, both isolates showed inhibition against cancer cells which were 35.45–76.39% |
(62) |
Hydrolysates of soy protein Flavorzyme (F-SPIH) |
VHVV |
Hypertensive rats |
Neuroprotective effect |
A peptide that is bioactive VHVV had stimulated CREB-induced downstream proteins that might decrease the long-term memory loss mediated by hypertension and maintain the survival of neurons |
(63, 64) |
Black soy |
– |
In vivo
|
Blood pressure |
Systolic blood pressure reduced clearly in peptide supplemented group (−9.69 ± 12.37 mm Hg) as compared to control (−2.91 ± 13.29 mm Hg) |
(65) |
Soy β-Conglycinin |
YVVNPDNDEN YVVNPDNNEN |
HepG2 Cells |
Hypocholesterolemic |
At 350 μM 1st peptide upregulates the mature SREBP2 protein level (134.0 ± 10.5%), enhanced the LDLR protein (152.0 ± 20.0%), and HMGCoA reductase protein (171 ± 29.9%), as compared to 2nd peptide where mature SREBP2 protein regulation was 158.0 ± 9.2%, the increase in LDL and HMGCoA reductase was 164.0 ± 17.9%, and 170 ± 50.0%, respectively |
(66) |
Glycinin |
IAVPTGVA |
Human intestinal Caco-2 cells and serum |
Anti-diabetic |
Stopped DPP-IV action in situ, with IC50 values 223.2 μM |
(67, 68) |
Glycinin and β-conglycinin, |
– |
Human intestinal Caco-2 cells |
Hypocholesterolemic Anti-Diabetic |
Peptides enhanced protein levels (51.5–63.0%, 55.2–85.8%) than control (0.5–1.0 mg/mL) moreover DPP-IV activity decreased (16.3–31.4% and 15.3–11.0%) than control (1.0 and 2.5 mg/mL) |
(69) |
Soybean protein isolate |
FDPAL |
Caenorhabditis elegans
|
Anti- oxidative |
Caused a remarkably increase in resistance to oxidative stress, upregulated the specific expression of genes in Caenorhabditis elegans
|
(70) |
Soybean glycinin |
VAWWMY |
Rats |
Anti- hypocholesterolemic |
Serum (0.03), liver (0.03), and intestine (0.2) detected low values of cholesterol |
(71) |
Soybean |
QRPR |
RAW 264.7 |
Anti-inflammation |
Soybean peptide reduced the cytokines levels such as TNF-α and IL-6 that are responsible for inflammation |
(72) |
Bacillus. licheniformis KN1G mediated soybean |
KFVPKQPNMIL |
Human ACE2 cell receptor |
Anti-viral |
Preventative measures against SARS-CoV-2 infection |
(16) |
Soybean fermented by Bacillus subtilis (KN2B and KN2M). |
ALPEEVIQHTFNLKSQ |
In silico
|
Anti-viral |
Effective against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). |
(16) |
Soybean induced peptide |
QRPR |
RAW264.7 cell model |
Anti-inflammation |
Autophagy was activated by QRPR in the inflammatory cell; however, autophagy was inhibited by reducing QRPR inhibitory effect |
(73, 74) |
R95, N98-4445A, S03-543CR |
– |
Human blood, breast, and prostate |
Anti-proliferative activity |
Showed up to 68.0% inhibition of cancer lines |
(75) |
Glycinin, β-conglycinin and lectin from soy milk |
HSYNLRQSQVSELKYEGNWGPLV NPESQQGSPRV |
In vitro
|
Anti-oxidative and anti-hypertensive effects |
Peptides (10 kDa) resulted maximum antioxidant and DDPH values as 1,831 ± 20.29 TEAC μm and 50.74 ± 0.27%, respectively while ace inhibition was 75.97 ± 1.5%. |
(76) |
Soybean |
VHVV |
Rats |
Antihypertensive |
Antioxidant defense induced, stabilized mitochondrial homeostasis, decreased renal damage, induced free radicals in rats |
(77) |
Alcalase and neutrase |
QNGEQE RGASADGPR YGGGGE |
Macrophage RAW264.7 cells |
Immunoregulatory effect |
The cell viabilities decreased from 97.61 to 115.01% to 86.65% |
(78) |
Soybean protein |
DGWFR ALSWLR DGWFRL PNGPVWR |
Mice model |
Sleep effects |
Mice provided with 0.65 g kg−1 soybean-derived peptides showed 59.21% sleep duration on 3rd day of observation and increased melatonin levels (95.31%) while with 2.60 g kg−1 peptides doubled the serotonin in the brain and increased the awaking situation |
(79) |
Alcalase low molecular weight fraction (SPH-I, MW < 3 kDa) |
VVFVDRL VIYVVDLR IYVVDLR IYVFVR |
Human intestinal Caco-2 cells |
Anti-oxidative effect |
Desirable results showed in the case of ORAC (143 ± 2.1–171 ± 4.8 μM TE/μM), FRAP (54.7 ± 1.2–79.0 ± 0.6 mM Fe2+/μM), radical-scavenging activity (3.42 ± 0.2–4.24 ± 0.4 mMTE/μM) and DPPH (16.5 ± 0.5–20.3 ± 1.0 μM (TE)/μM). SPH-IC (85.9%) and SPH-ID (96.2%) restrained maximum H2O2-induced ROS generation |
(80) |
Lunasin, lectin |
SKWQHQQDSCRKQKQGVNLTPCEK HIMEKIQGRGDDDDDDDDD |
Cancer cells of the human breast |
Anti-cancer effect |
MDA-MB-231 cells were inhibited with these bioactive peptides (glycitein, Genistein, β-sitosterol, and genistin) while 142.67 ± 5.88 μM, 93.75 ± 5.15 μM, 196.28 ± 4.45 μM and 127.82 ± 4.70 μM and values were detected |
(81) |